UPDATE 2-India's Gland Pharma to make up to 252 mln Sputnik V vaccine doses
Adds details on vaccine, background
BENGALURU, March 16 (Reuters) - Gland Pharma Ltd GLAD.NS said on Tuesday it had struck a deal with the Russian Direct Investment Fund (RDIF) to make up to 252 million doses of the Sputnik V COVID-19 vaccine, bringing India's total production of the shot to at least 352 million.
Shares of Gland Pharma, which is backed by China-based Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS, surged as much as 9.5% to hit a record high of 2,783.85 rupees.
India's Hetero already has a deal in place to produce over 100 million doses of the vaccine, which has proven to be 91.6% effective against COVID-19.
Sputnik V, developed by Moscow's Gamaleya Institute, has been approved in 22 countries, with the RDIF signing supply deals with over 13 countries.
Indian drugmaker Dr.Reddy's Laboratories Ltd REDY.NS has also been holding small clinical studies of Sputnik V domestically. It had sought emergency use approval for the vaccine last month, but India's drug regulator had asked for more data.
Production is expected to begin in the third quarter at its facilities in Hyderabad, with deliveries estimated in the final quarter of the year, Gland Pharma said in a statement. It did not specify which countries it would supply the doses to.
Gland Pharma also said it would explore more deals for the vaccine.
India, the world's biggest vaccine maker, has so far given emergency use approval to AstraZeneca Plc's AZN.L shot and a homegrown vaccine made by Bharat Biotech. It has donated or sold vaccines to more than three dozen countries, while significantly ramping up its own inoculation program this month.
European Union (EU) governments are considering launching talks with Sputnik V developers as the EU tries to get its vaccination program back on track, EU diplomatic and official sources have told Reuters. nL8N2L73QG
(Reporting by Anuron Kumar Mitra in Bengaluru; Editing by Devika Syamnath and Anil D'Silva)
((AnuronKumar.Mitra@thomsonreuters.com; +91 99863 58469;))